Observatory of Patients With MyeloProliferative Neoplasm Treated With Anti-inflammatory Immunotherapy
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 100
- 试验地点
- 1
- 主要终点
- Efficacy of the anti-inflammatory immunotherapy
研究概览
简要总结
The study will collect cases of MPN patients who also benefit from an anti-inflammatory immunotherapy for another disease. Efficacy and tolerability of the drug will be assessed in this population.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •MyeloProliferative Neoplasm diagnosis
- •receiving or having received an immunotherapy targeting IL-1, IL-6, IL-17, IL-23 or TNF
排除标准
- •Unable to consent
结局指标
主要结局
Efficacy of the anti-inflammatory immunotherapy
时间窗: 1 year
Depending on the indication of the anti-inflammatory treatment, clinical efficacy will be assessed clinically as number of patients reaching complete (total disappearance of initial symptoms- diarrhea, arthritis, fever, skin lesions), partial (improvement of symptoms, but not total disappearance) or absence of response (the treatment did not improve the symptoms). Clinical judgement will be according to the physician appreciation.
Tolerability of the anti-inflammatory immunotherapy
时间窗: 1 year
Tolerability will be assessed as the number of reported unexpected side effects attributed to the treatment as judged by the caring physician, including treatment discontinuation
次要结局
未报告次要终点